US 11,717,684 B2
Nanoparticles for use for treating a neuronal disorder
Marie-Edith Meyre, Saint Mande (FR); Agnès Pottier, Paris (FR); and Laurent Levy, Paris (FR)
Assigned to NANOBIOTIX S.A., Paris (FR)
Filed by NANOBIOTIX S.A., Paris (FR)
Filed on Mar. 18, 2022, as Appl. No. 17/697,976.
Application 17/697,976 is a continuation of application No. 16/472,214, granted, now 11,278,723, previously published as PCT/EP2017/083533, filed on Dec. 19, 2017.
Claims priority of application No. 16306750 (EP), filed on Dec. 21, 2016.
Prior Publication US 2022/0212008 A1, Jul. 7, 2022
Int. Cl. A61P 25/00 (2006.01); A61N 1/36 (2006.01); A61K 41/00 (2020.01); A61N 2/00 (2006.01); B82Y 40/00 (2011.01)
CPC A61N 1/36025 (2013.01) [A61K 41/0052 (2013.01); A61N 2/006 (2013.01); A61P 25/00 (2018.01); B82Y 40/00 (2013.01)] 5 Claims
OG exemplary drawing
 
1. A method for normalizing impaired synchronization of oscillations within and/or between neuronal networks within and/or between distinct regions of the brain in a patient in need thereof, wherein the method comprises i) administering a composition to the subject, the composition comprising nanoparticles and/or nanoparticles aggregates and a pharmaceutically acceptable support, and the nanoparticle or nanoparticles aggregate material being selected from a conductor material selected from a metal having a standard reduction potential E° above 0.2 selected from Pd, Pt and Au, and an intrinsic semiconductor material with a band gap Eg below 3.0 eV selected from an element from group IVA of the Mendeleev's periodic table, a mixed composition of elements from groups III and V of the Mendeleev's periodic table, and a mixed composition of elements from group II and VI of the Mendeleev periodic table, and ii) exposing the subject to an electric field.